乳腺癌内分泌治疗现状
| 作者: |
1王娟娟,
1李建,
1柴源,
1刘斌
1 延安大学附属医院普外科，陕西 延安 716000 |
| 通讯: |
刘斌
Email: linbin070806@sohu.com |
| DOI: | 10.3978/j.issn.2095-6959.2015.01.024 |
摘要
内分泌治疗是雌激素受体阳性乳腺癌患者的重要治疗方法。随着新的内分泌药物出现，乳腺癌的 内分泌治疗也取得了新的进展。目前，治疗绝经前乳腺癌患者的标准用药仍是他莫昔芬，对于绝 经后乳腺癌患者使用芳香化酶抑制剂会获得更大的临床疗效。本文主要阐述内分泌治疗在乳腺癌 中的应用。
关键词：
乳腺癌
内分泌治疗
他莫昔芬
芳香化酶抑制剂
新辅助疗法
The current endocrine therapy for breast cancer
CorrespondingAuthor: LIU Bin Email: linbin070806@sohu.com
DOI: 10.3978/j.issn.2095-6959.2015.01.024
Abstract
Endocrine therapy forms a central modality in the treatment of estrogen receptor positive breast cancer. The endocrine therapy for breast cancer has made progress with the development of new endocrine drugs. Now, tamoxifen is still the standard endocrine therapeutic drug for the premenopausal patients, but aromatase inhibitors can bring more clinical effect for the postmenopausal patients. This review details the current endocrine therapy utilized in breast cancer.